CERo Therapeutics Holdings Gestione

Gestione criteri di controllo 0/4

CERo Therapeutics Holdings Il CEO è Chris Ehrlich, nominato in Sep2024, ha un mandato di meno di un anno. possiede direttamente 3.86% delle azioni della società, per un valore di $ 851.92K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 0.1 anni e 0.8 anni.

Informazioni chiave

Chris Ehrlich

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	3.9%
Durata media del management	less than a year
Durata media del Consiglio di amministrazione	less than a year

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Chris Ehrlich (54 yo)

less than a year

Mandato

Mr. Christopher B. Ehrlich, M.B.A. also known as Chris, serves as Chief Executive Officer & Chair of CERo Therapeutics, Inc. Mr. Ehrlich was Director at ProLynx Inc since September 2022 until 2023. He serv...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Ehrlich	CEO & Chair	less than a year	Nessun dato	3.86% $ 851.9k
Brian Atwood	President & Director	no data	Nessun dato	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	Nessun dato	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	Nessun dato	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	Nessun dato	0% $ 0

0.08yrs

Durata media

54yo

Età media

Gestione esperta: Il team dirigenziale di CERO non è considerato esperto (durata media 0.1 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Christopher Ehrlich	CEO & Chair	less than a year	Nessun dato	3.86% $ 851.9k
Brian Atwood	President & Director	less than a year	Nessun dato	13.13% $ 2.9m
Lawrence Corey	Co-founder & Head of Scientific Advisory Board	no data	Nessun dato	5.62% $ 1.2m
Andrew Kucharchuk	CFO & Director	less than a year	Nessun dato	0% $ 0
Kristen Pierce	Chief Development Officer & Director	less than a year	Nessun dato	0% $ 0
Kathleen LaPorte	Independent Director	less than a year	Nessun dato	0.65% $ 142.9k
Shami Patel	Independent Director	less than a year	Nessun dato	Nessun dato
Adrian Bot	Scientific Advisor	no data	Nessun dato	Nessun dato
Antonio Lanzavecchia	Scientific Advisor	no data	Nessun dato	Nessun dato
Rafi Ahmed	Scientific Advisor	no data	Nessun dato	Nessun dato
Michael Byrnes	Independent Director	less than a year	Nessun dato	0% $ 0
Lindsey Rolfe	Independent Director	less than a year	Nessun dato	0% $ 0

0.8yrs

Durata media

55yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CERO non è considerato esperto (durata media del mandato 0.8 anni), il che suggerisce un nuovo consiglio.

CERo Therapeutics Holdings Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

High number of new and inexperienced directors

Recent updates

CERo Announces Reverse Stock Split to Regain Compliance with the Bid Price Requirement

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

Nasdaq Determines to Delist CERo Therapeutics Holdings' Securities from The Nasdaq Global Market on November 8, 2024 Due to Failure to Regain Compliance with the MVLS Requirement within the Cure Period

CERo Therapeutics Holdings Receives Low Price Deficiency Letter from Nasdaq and Nasdaq Determines to Delist its Securities from The Nasdaq Global Market

CERo Therapeutics Holdings, Inc. Announces Submission of IND Clinical Hold Complete Response Letter

CERo Therapeutics Holdings, Inc. Appoints Shami Patel to the Board as Class III Director

CERo Therapeutics Holdings, Inc. Appoints Andrew Albert Kucharchuk as Chief Financial Officer

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.2 million in funding

CERo Therapeutics Holdings, Inc. announced that it expects to receive $1.25 million in funding

CERo Therapeutics Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement and MVPHS Requirement

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

CERo Therapeutics Holdings, Inc. announced delayed 10-Q filing

CERo Therapeutics Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum $50 Million Market Value of Listed Securities Requirement Set Forth in Nasdaq Listing Rule 5450(b)(2)(A)

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

CERo Therapeutics Holdings, Inc. announced delayed annual 10-K filing

New major risk - Shareholder dilution

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

CERo Therapeutics, Inc. Announces Publication of Preclinical Research Supporting the Use of its Clinical Candidate CER-1236 to Treat AML Patients

Phoenix Biotech Acquisition Corp.(NasdaqGM:CERO) dropped from NASDAQ Composite Index

CERo Therapeutics Holdings, Inc. announced that it has received $9.4 million in funding

New minor risk - Share price stability

Phoenix Biotech Acquisition Corp. announced that it expects to receive $2 million in funding from Keystone Capital Partners LLC

High number of new and inexperienced directors

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

Phoenix Biotech Acquisition Corp. Receives Non-Compliance Letter from Nasdaq related to Listing Rule 5450(a)(2

CERo Therapeutics, Inc. entered into a definitive business combination agreement to acquire Phoenix Biotech Acquisition Corp. (NasdaqGM : PBAX) in a reverse merger transaction for an implied enterprise value of approximately $110 million.

Phoenix Biotech Acquisition Corp. (NasdaqGM:PBAX) entered into a business combination agreement to acquire Intrinsic Medicine, Inc. for approximately $140 million.

AMMINISTRATORE DELEGATO

Mandato

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media